T. Hovey

发表

Selumetinib Plus Adjuvant Radioactive Iodine in Patients With High-Risk Differentiated Thyroid Cancer: A Phase III, Randomized, Placebo-Controlled Trial (ASTRA)

R. Paschke, Karen So, L. Bastholt, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Patient-reported outcomes from FLAURA: Osimertinib versus erlotinib or gefitinib in patients with EGFR-mutated advanced non-small-cell lung cancer.

S. Novello, B. Cho, N. Leighl, 2019, European journal of cancer.

139PD Patient-reported outcomes from FLAURA: Osimertinib versus standard of care (SoC) epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) in patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC)

S. Novello, B. Cho, N. Leighl, 2018 .